Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.38B, +7.3% YoY · Filed Oct 28, 2026
Bausch & Lomb Corp (BLCO) files with the SEC under industry code 3851, Ophthalmic Goods. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.4 billion and net income of $32.0 million. Free cash flow was $178.0 million. As of Sep 30, 2026 it held $513.0 million in cash and investments and $5.0 billion in total debt.
Revenue
$1.38B
+7.3% vs year-ago quarter
Net income
$32.00M
+214.3% vs year-ago quarter
Operating cash flow
$233.00M
+70.1% vs year-ago quarter
Free cash flow
$178.00M
+182.5% vs year-ago quarter
EPS
$0.09
+212.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
357.50M
+0.9% vs year-ago quarter
Net cash
$-4.50B
Q3 FY2026
Operating margin
7.1%
TTM
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- BLCO (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Vaughan, Ontario, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1860742
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- RxSight, Inc. RXST
- Innovative Eyewear Inc LUCY
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.2B | $1.4B | $1.3B |
| Operating income | $155.0M | $83.0M | $33.0M | $112.0M | $95.0M |
| Net income | $32.0M | -$14.0M | -$71.0M | -$58.0M | -$28.0M |
| Diluted EPS | $0.09 | -$0.04 | -$0.20 | -$0.16 | -$0.08 |
| Operating cash flow | $233.0M | $153.0M | $32.0M | $136.0M | $137.0M |
| Free cash flow | $178.0M | $82.0M | -$68.0M | $60.0M | $63.0M |
| Total assets | $14.0B | $13.9B | $13.8B | $14.0B | $13.8B |
| Total liabilities | $7.4B | $7.4B | $7.3B | $7.5B | $7.3B |
| Stockholders' equity | $6.4B | $6.4B | $6.4B | $6.4B | $6.4B |
| Cash and investments | $513.0M | $367.0M | $268.0M | $383.0M | $310.0M |
| Total debt | $5.0B | $5.1B | $5.0B | $5.2B | $5.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 13, 2026 | Oct 11, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 12, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Aug 6, 2026 | Aug 5, 2026 |
All 371 Bausch & Lomb Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.